ArticlePloS one2025
Global burden of polycystic ovary syndrome in women of reproductive age, 1990-2021: Analysis of the global burden of disease study 2021 with projections to 2050.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Burden of polycystic ovary syndrome in low-and middle-income countries, 1990-2023: results from the global burden of disease study 2023.Tropical medicine and health · 2026Article
- Advancing Maternal Health with Long-Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies.Clinical pharmacology and therapeutics · 2026Review
- Global, regional and national burden of polycystic ovary syndrome: historical trends from 1990 to 2021 and projections to 2035.Frontiers in endocrinology · 2026Article
- Non-linear saturation threshold of gonadotropin dose on cumulative live birth rates in advanced-age women with polycystic ovary syndrome: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Exploring the impact of endocrine-disrupting chemicals on erectile dysfunction through network toxicology and machine learning.BMC pharmacology & toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the global burden of polycystic ovary syndrome (PCOS) among women of reproductive age from 1990 to 2021.
methodsThis study analyzed population-based data from the Global Burden of Disease (GBD) database on the incidence, prevalence, and disability-adjusted life years (DALYs) of PCOS in reproductive-aged women. Age-standardized rates for incidence (ASIR), prevalence (ASPR), and DALYs (ASDR) were calculated per 100,000 population, with 95% uncertainty intervals (UIs). Data from 204 countries and territories were stratified by age, location, and socio-demographic index (SDI).
resultsGlobally, the burden of PCOS among reproductive-aged women in 2021 was characterized by ASIR of 64.44 (95% UI: 39.07, 103.40) per 100,000 population, ASPR of 3364.53 (95% UI: 2395.08, 4681.81) per 100,000 population, and ASDR of 29.51 (95% UI: 13.09, 61.49) per 100,000 population. Moreover, the pace of increase in ASIR, ASPR, and ASDR accelerated during 1990-2021, with estimated annual percentage change (EAPC) of 0.65 (95% CI: 0.62, 0.69), 0.74 (95% CI: 0.70, 0.77), and 0.72 (95% CI: 0.68, 0.76), respectively. Among the five SDI regions, the middle SDI region exhibited the highest EAPCs for incidence (1.39; 95% CI: 1.34, 1.43), prevalence (1.39; 95% CI: 1.34, 1.43), and DALYs (1.73; 95% CI: 1.69, 1.78). Regionally, the High-income Asia Pacific region demonstrated the highest ASIR of 308.16 (95% UI: 485.83, 171.53) per 100,000 population. At the national level, Japan exhibited the highest ASIR of 360.92 (95% UI: 199.08, 573.59) per 100,000 population.
conclusionThe global burden of PCOS among women of reproductive age has shown a consistent upward trend in incidence, prevalence, and DALYs. A comprehensive understanding of the epidemiology of PCOS among women of reproductive age is essential for informing targeted prevention strategies and optimizing disease control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.